StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

Lexaria Bioscience r&d expenses

Research and development expenses are spending on new products and technology.

Lexaria Bioscience's R&D Expenses for the twelve months ending May 31, 2026 was $4.00M, down 45.4% year over year. For fiscal 2025 it was $8.24M, up 249.0% from the year before. Over ten years it grew 49.6% a year on average. The highest annual figure on record is $8.24M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Aug 31, 2025$8.24M+249.0%
FY2024Aug 31, 2024$2.36M-35.6%
FY2023Aug 31, 2023$3.67M+99.0%
FY2022Aug 31, 2022$1.84M+45.9%
FY2021Aug 31, 2021$1.26M+226.3%
FY2020Aug 31, 2020$387.07K-30.3%
FY2019Aug 31, 2019$555.73K+12.8%
FY2018Aug 31, 2018$492.86K+809.6%
FY2017Aug 31, 2017$54.19K+500.5%
FY2016Aug 31, 2016$9.02K-93.8%
FY2015Aug 31, 2015$146.47K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026May 31, 2026$970.83K-64.3%
Q2 FY2026CQ1 2026Feb 28, 2026$475.39K-71.8%
Q1 FY2026CQ4 2025Nov 30, 2025$671.34K-65.6%
Q4 FY2025CQ3 2025Aug 31, 2025$1.88M+94.6%
Q3 FY2025CQ2 2025May 31, 2025$2.72M+374.2%
Q2 FY2025CQ1 2025Feb 28, 2025$1.69M+585.9%
Q1 FY2025CQ4 2024Nov 30, 2024$1.95M+240.0%
Q4 FY2024CQ3 2024Aug 31, 2024$967.21K+93.3%
Q3 FY2024CQ2 2024May 31, 2024$573.09K-65.1%
Q2 FY2024CQ1 2024Feb 29, 2024$245.78K-64.7%
Q1 FY2024CQ4 2023Nov 30, 2023$574.49K-30.7%
Q4 FY2023CQ3 2023Aug 31, 2023$500.41K+40.5%
Q3 FY2023CQ2 2023May 31, 2023$1.64M+118.1%
Q2 FY2023CQ1 2023Feb 28, 2023$696.18K+152.5%
Q1 FY2023CQ4 2022Nov 30, 2022$829.49K+80.8%
Q4 FY2022CQ3 2022Aug 31, 2022$356.19K-19.0%
Q3 FY2022CQ2 2022May 31, 2022$752.10K+65.5%
Q2 FY2022CQ1 2022Feb 28, 2022$275.69K+56.3%
Q1 FY2022CQ4 2021Nov 30, 2021$458.71K+138.6%
Q4 FY2021CQ3 2021Aug 31, 2021$439.79K+542.1%
Q3 FY2021CQ2 2021May 31, 2021$454.44K+1750.6%
Q2 FY2021CQ1 2021Feb 28, 2021$176.40K-5.4%
Q1 FY2021CQ4 2020Nov 30, 2020$192.26K+78.9%
Q4 FY2020CQ3 2020Aug 31, 2020$68.50K-57.6%
Q3 FY2020CQ2 2020May 31, 2020$24.56K-89.4%
Q2 FY2020CQ1 2020Feb 29, 2020$186.56K+182.3%
Q1 FY2020CQ4 2019Nov 30, 2019$107.46K+10.8%
Q4 FY2019CQ3 2019Aug 31, 2019$161.64K-24.3%
Q3 FY2019CQ2 2019May 31, 2019$231.04K+148.2%
Q2 FY2019CQ1 2019Feb 28, 2019$66.08K-12.8%
Q1 FY2019CQ4 2018Nov 30, 2018$96.97K-12.2%
Q4 FY2018CQ3 2018Aug 31, 2018$213.64K+591.3%
Q3 FY2018CQ2 2018May 31, 2018$93.07K+1029.5%
Q2 FY2018CQ1 2018Feb 28, 2018$75.76K+874.1%
Q1 FY2018CQ4 2017Nov 30, 2017$110.39K+1420.3%
Q4 FY2017CQ3 2017Aug 31, 2017$30.91K+83429.7%
Q3 FY2017CQ2 2017May 31, 2017$8.24K–
Q2 FY2017CQ1 2017Feb 28, 2017$7.78K–
Q1 FY2017CQ4 2016Nov 30, 2016$7.26K–
Q4 FY2016CQ3 2016Aug 31, 2016$37–

More Lexaria Bioscience figures

See a number that looks wrong?